Helix BioPharma Corp., a clinical-stage oncology company developing therapies for difficult-to-treat cancers, has announced the appointment of Markus Loeffler, MD, MBA, as Chief Medical Officer (CMO). The appointment comes as the company prepares to enter a more execution-focused phase of clinical development, with multiple programs approaching key regulatory and clinical milestones.
Dr. Loeffler will lead the strategy and execution of Helix's clinical programs, including the planned Phase Ib/II evaluation of L-DOS47 in combination with pembrolizumab in first-line non-small cell lung cancer (NSCLC). He will also guide LEUMUNA™ toward clinical development for leukemia relapse following allogeneic stem cell transplantation.
Thomas Mehrling, MD, PhD, Chief Executive Officer of Helix, expressed confidence in Dr. Loeffler's abilities, stating, "I've had the privilege of working with Markus before, and I have seen firsthand his ability to translate innovative science into well-executed clinical development programs. He is an outstanding clinical development leader with a strong track record of advancing innovative oncology therapies through the development pathway. His expertise will be instrumental as we advance L-DOS47 into its next stage of clinical development and prepare LEUMUNA to enter the clinic."
Dr. Loeffler brings more than three decades of leadership in oncology drug development. He has extensive experience advancing oncology therapeutics, including small molecules, biologics, antibody-drug conjugates (ADCs), radiopharmaceuticals, and immunotherapies, from early clinical development through Phase III and regulatory approval. Throughout his career, he has held senior clinical development and CMO roles at leading biotechnology and pharmaceutical companies, including Roche, Advanced Accelerator Applications, Mundipharma, NH TherAguix, Corbus Pharmaceuticals, and SK Life Science. Notably, Dr. Loeffler led the pivotal Phase III clinical program for Lutathera®, which was subsequently approved for the treatment of certain gastroenteropancreatic neuroendocrine tumors.
Dr. Loeffler commented on his new role, saying, "I'm excited to join Helix at such an important stage in its evolution. The Company's pipeline combines strong scientific foundations with clear clinical development opportunities. I am particularly enthused by the opportunity to advance L-DOS47 in combination with checkpoint inhibition and to bring LEUMUNA toward its first clinical evaluation. I look forward to working alongside the team to translate these programs into meaningful new treatment options for patients with difficult-to-treat cancers."
Helix BioPharma is focused on developing therapies for underserved patient populations with difficult-to-treat cancers. The company's pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate being developed as a combination therapy for non-small cell lung cancer. Additional pipeline candidates include LEUMUNA, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA, a pre-IND gemcitabine prodrug for advanced solid tumors.
The appointment of Dr. Loeffler is significant as Helix prepares to advance its lead candidate L-DOS47 into a combination study with pembrolizumab, a checkpoint inhibitor, in first-line NSCLC. This move underscores the company's commitment to exploring combination therapies that may improve outcomes for patients with difficult-to-treat cancers. The experience Dr. Loeffler brings, particularly his success with Lutathera, could be instrumental in navigating the regulatory and clinical development pathways for Helix's pipeline.
For more information about Helix BioPharma, visit https://www.helixbiopharma.com/.
